Real-world effectiveness of vedolizumab in refractory pouchitis: a focus on biomarker changes during intravenous to subcutaneous transition (POUCHIVED study)
VDZ is effective and safe for the management of CARP, particularly when used at first line in the treatment course. Transitioning from IV to SC administration maintains clinical remission and is well tolerated in real-world clinical settings.
Authors
- Alejandro Mínguez (ORCID: https://orcid.org/0000-0002-5825-1377)
- José María Huguet (ORCID: https://orcid.org/0000-0001-6486-1262)
- X Serra-Ruiz
- Marisa Iborra (ORCID: https://orcid.org/0000-0001-7360-7581)
- Francisco Mesonero (ORCID: https://orcid.org/0000-0002-7864-8187)
- María Dolores Martin‐Arranz (ORCID: https://orcid.org/0000-0002-1872-0917)
- Rocío Ferreiro‐Iglesias (ORCID: https://orcid.org/0000-0002-0469-4332)
- Inma Lorca
- Raquel Vicente-Lidón
- Leticia Gimeno‐Pitarch (ORCID: https://orcid.org/0000-0002-6871-9367)
- Beatriz Sicilia (ORCID: https://orcid.org/0000-0002-4495-9358)
- P. Gálvez-Martín
- Pilar Nos (ORCID: https://orcid.org/0000-0002-6619-1511)
- Manuel Barreiro-de Acosta
- Elena Céspedes-Martínez (ORCID: https://orcid.org/0000-0003-4943-2181)
Institutions
- Hospital Universitario La Paz (ES)
- Hospital Clínico Universitario de Valencia (ES)
- Complejo Hospitalario Universitario de Santiago (ES)
- Hospital Universitario Miguel Servet (ES)
- Hospital Universitario de Burgos (ES)
- Hospital General Universitari de Castelló (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Hospital General Universitario De Valencia (ES)
- Hospital Universitario Ramón y Cajal (ES)
- Instituto de Investigación Sanitaria La Fe (ES)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-17
- DOI
- https://doi.org/10.3389/fimmu.2025.1630678
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00